Applied Molecular Transport Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase ...
07 4월 2021 - 5:01AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced the
closing of its previously announced underwritten public offering of
2,875,000 shares of its common stock, which includes the exercise
in full of the underwriters’ option to purchase 375,000 additional
shares of its common stock, at a public offering price of $42.00
per share. All of the shares of common stock were offered by AMT.
The aggregate gross proceeds to AMT from the offering were
approximately $120.8 million, before deducting underwriting
discounts and commissions and other offering expenses.
BofA Securities, Jefferies, and SVB Leerink
acted as joint book-running managers for the offering.
The registration statement relating to these
securities became effective on March 31, 2021. The offering was
made only by means of a prospectus, copies of which may be obtained
from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001, Attention: Prospectus Department,
or by email at dg.prospectus_requests@bofa.com; Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by email at prospectus_department@Jefferies.com; or
SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
A copy of the registration statement can be accessed through the
SEC’s website at www.sec.gov.
About Applied Molecular Transport
Inc.Applied Molecular Transport Inc. is a clinical-stage
biopharmaceutical company leveraging its proprietary technology
platform to design and develop a pipeline of novel oral biologic
product candidates to treat autoimmune, inflammatory, metabolic,
and other diseases. AMT’s proprietary technology platform allows it
to exploit existing natural cellular trafficking pathways to
facilitate the active transport of diverse therapeutic modalities
across the intestinal epithelium (IE) barrier. Active transport is
an efficient mechanism that uses the cell’s own machinery to
transport materials across the IE barrier. AMT believes that its
ability to exploit this mechanism is a key differentiator of its
approach. AMT is developing additional oral biologic product
candidates in patient-friendly oral forms that are designed to
either target local gastrointestinal tissue or enter systemic
circulation to precisely address the relevant biology of a
disease.
Investor Relations
Contact:Andrew ChangHead, Investor Relations &
Corporate Communicationsachang@appliedmt.com
Media Contacts:Alexandra
SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Applied Molecular Transp... (NASDAQ:AMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024